UY34669A - COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO. - Google Patents

COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.

Info

Publication number
UY34669A
UY34669A UY0001034669A UY34669A UY34669A UY 34669 A UY34669 A UY 34669A UY 0001034669 A UY0001034669 A UY 0001034669A UY 34669 A UY34669 A UY 34669A UY 34669 A UY34669 A UY 34669A
Authority
UY
Uruguay
Prior art keywords
piridazine
imidazo
compositions
methods
compounds based
Prior art date
Application number
UY0001034669A
Other languages
English (en)
Inventor
Bi Yingzhi
Kenneth Gordon Carson
Cianchetta Giovanni
Michael Alan Green
Kumi Godwin
Zhang Yulian
Glenn Gregory Zipp
Liang Zhi
Ying Jade Liu
Main Alan
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of UY34669A publication Critical patent/UY34669A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se describen compuestos en base a imidazo[1,2-b]piridazina de la fórmula en donde R1, R2 y R3 se definen en la presente. También se describen composiciones que comprenden los compuestos y métodos para su uso para tratar, manejar y/o prevenir enfermedades y trastornos mediados por la actividad de la quinasa asociada al adaptador 1.
UY0001034669A 2012-03-09 2013-03-11 COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO. UY34669A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261608758P 2012-03-09 2012-03-09

Publications (1)

Publication Number Publication Date
UY34669A true UY34669A (es) 2013-10-31

Family

ID=48014284

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034669A UY34669A (es) 2012-03-09 2013-03-11 COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.

Country Status (20)

Country Link
US (3) US8969565B2 (es)
EP (1) EP2822559B1 (es)
JP (1) JP6418949B2 (es)
KR (1) KR102085121B1 (es)
CN (1) CN104470523B (es)
AR (1) AR090291A1 (es)
AU (1) AU2013230119B2 (es)
BR (1) BR112014022271B1 (es)
CA (1) CA2866164C (es)
ES (1) ES2676826T3 (es)
HK (1) HK1203407A1 (es)
IL (1) IL234485A (es)
MX (1) MX347917B (es)
NZ (1) NZ630719A (es)
RU (1) RU2014140739A (es)
SG (1) SG11201405563VA (es)
TW (1) TW201341385A (es)
UY (1) UY34669A (es)
WO (1) WO2013134219A1 (es)
ZA (1) ZA201406148B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210891A1 (en) * 2009-01-26 2010-07-28 Domain Therapeutics New adenosine receptor ligands and uses thereof
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
TR201808280T4 (tr) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pirazolo[1,5-a]pirimidin-bazlı bileşikler, bunları içeren bileşimler, ve bunların kullanım usulleri.
US8901305B2 (en) 2012-07-31 2014-12-02 Bristol-Myers Squibb Company Aryl lactam kinase inhibitors
CN105121445A (zh) 2013-02-22 2015-12-02 百时美施贵宝公司 作为连接蛋白相关激酶1(AAK1)抑制剂的5H-色烯并[3,4-c]吡啶
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CN105979950A (zh) 2013-10-11 2016-09-28 百时美施贵宝公司 吡咯并三嗪激酶抑制剂
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
MY193524A (en) * 2014-01-24 2022-10-18 Turning Point Therapeutics Inc Diaryl macrocycles as modulators of protein kinases
JP6441947B2 (ja) * 2014-01-31 2018-12-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ キノリンを基にしたキナーゼ阻害剤
TW201620911A (zh) * 2014-03-17 2016-06-16 雷西肯製藥股份有限公司 銜接子關聯激酶１之抑制劑、包含其之組成物、及其使用方法
WO2016053794A1 (en) * 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
AU2015342883B2 (en) 2014-11-06 2020-07-02 Bial - R&D Investments, S.A. Substituted pyrrolo(1,2-a)pyrimidines and their use in the treatment of medical disorders
EP3215511B1 (en) 2014-11-06 2024-04-17 Bial-R&D Investments, S.A. Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
ES2958391T3 (es) 2014-11-06 2024-02-08 Bial R&D Invest S A Imidazo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
US10174044B2 (en) 2015-04-10 2019-01-08 Bristol-Myers Squibb Company Fused pyridines as kinase inhibitors
KR102599788B1 (ko) 2015-07-02 2023-11-07 터닝 포인트 테라퓨틱스, 인크. 단백질 키나제의 조절물질로서 키랄 디아릴 매크로사이클
LT3319969T (lt) * 2015-07-06 2024-06-10 Turning Point Therapeutics, Inc. Diarilo makrociklo polimorfas
JP6817287B2 (ja) * 2015-07-21 2021-01-20 ターニング・ポイント・セラピューティクス・インコーポレイテッドＴｕｒｎｉｎｇ Ｐｏｉｎｔ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． キラルジアリール大環状分子及びその使用
WO2017087590A1 (en) * 2015-11-18 2017-05-26 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
EP3440080A4 (en) 2016-04-06 2020-01-22 Lysosomal Therapeutics Inc. PYRAZOLO [1,5-A] PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
US11124516B2 (en) 2016-04-06 2021-09-21 BIAL-BioTech Investments, Inc. Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
AU2017250302B2 (en) * 2016-04-15 2021-01-21 Blueprint Medicines Corporation Inhibitors of activin receptor-like kinase
US11345698B2 (en) 2016-05-05 2022-05-31 Bial—R&D Investments, S.A. Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
US10689400B2 (en) 2016-07-28 2020-06-23 Turning Point Therapeutics, Inc. Macrocycle kinase inhibitors
GB201617758D0 (en) 2016-10-20 2016-12-07 Almac Discovery Limited Pharmaceutical compounds
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
KR20180088113A (ko) * 2017-01-26 2018-08-03 한미약품 주식회사 이미다조피리다진 화합물
AU2018234027B2 (en) * 2017-03-14 2021-12-09 Daiichi Sankyo Company, Limited Method for producing 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative
CN107082828B (zh) * 2017-05-19 2019-09-17 暨南大学 一种活性氧响应性高分子载体及其制备方法
CN111182903A (zh) 2017-07-28 2020-05-19 特普医药公司 巨环化合物及其用途
US10899733B2 (en) 2017-08-23 2021-01-26 Oregon Health & Science University Inhibitors of PARPs that catalyze mono-ADP-ribosylation
EP4151641A1 (en) 2017-12-19 2023-03-22 Turning Point Therapeutics, Inc. Macrocyclic compounds for treating cancer
KR20210146290A (ko) 2019-02-12 2021-12-03 스미토모 다이니폰 파마 온콜로지, 인크. 헤테로시클릭 단백질 키나제 억제제를 포함하는 제제
CN110684028B (zh) * 2019-10-28 2021-10-26 上海阿拉丁生化科技股份有限公司 一种2，6-二氮杂双环[3，3，0]辛烷类化合物的制备方法
CA3176337A1 (en) * 2020-04-21 2021-10-28 Peter King Rna-binding protein multimerization inhibitors and methods of use thereof
KR102590444B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 치료용 조성물
KR102590438B1 (ko) * 2020-10-16 2023-10-18 김홍렬 Pmca 억제제를 포함하는 코로나바이러스 감염 또는 감염 질환의 예방 또는 소독용 조성물
JP2024506909A (ja) * 2021-02-12 2024-02-15 ニンバス サターン， インコーポレイテッド Ｈｐｋ１アンタゴニスト及びその使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
US7750000B2 (en) * 2005-09-02 2010-07-06 Bayer Schering Pharma Ag Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
WO2008030579A2 (en) * 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
CN101522682A (zh) * 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
FR2934994B1 (fr) * 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
CN103965200B (zh) * 2008-09-22 2016-06-08 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
TR201808280T4 (tr) 2012-03-09 2018-07-23 Lexicon Pharmaceuticals Inc Pirazolo[1,5-a]pirimidin-bazlı bileşikler, bunları içeren bileşimler, ve bunların kullanım usulleri.
AU2013230066A1 (en) 2012-03-09 2014-09-25 Lexicon Pharmaceuticals, Inc. Inhibition of adaptor associated kinase 1 for the treatment of pain

Also Published As

Publication number Publication date
RU2014140739A (ru) 2016-04-27
CN104470523A (zh) 2015-03-25
KR20140138865A (ko) 2014-12-04
AR090291A1 (es) 2014-11-05
IL234485A (en) 2017-02-28
HK1203407A1 (en) 2015-10-30
MX347917B (es) 2017-05-17
TW201341385A (zh) 2013-10-16
EP2822559A1 (en) 2015-01-14
CA2866164A1 (en) 2013-09-12
ZA201406148B (en) 2016-06-29
CA2866164C (en) 2020-07-07
JP2015509534A (ja) 2015-03-30
AU2013230119B2 (en) 2017-02-23
CN104470523B (zh) 2017-07-11
BR112014022271B1 (pt) 2021-09-21
KR102085121B1 (ko) 2020-03-05
US8969565B2 (en) 2015-03-03
NZ630719A (en) 2017-01-27
US20130245021A1 (en) 2013-09-19
WO2013134219A1 (en) 2013-09-12
AU2013230119A1 (en) 2014-09-25
BR112014022271A2 (es) 2017-06-20
MX2014010584A (es) 2014-09-18
ES2676826T3 (es) 2018-07-25
US20170057964A1 (en) 2017-03-02
JP6418949B2 (ja) 2018-11-07
US20160024093A1 (en) 2016-01-28
SG11201405563VA (en) 2014-10-30
EP2822559B1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
UY34668A (es) COMPUESTOS EN BASE A PIRAZOLO[1,5-a]PIRIMIDINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
CL2017003205A1 (es) Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen.
UY34632A (es) Compuestos de oxazolidin- 2- ona y usos de los mismos
SV2018005792A (es) Nuevos derivados piperidinilo sustituidos con hetero (arilo), un proceso para su preparacion y composiciones farmaceuticas que los contienen
SV2017005590A (es) Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen
CO7210068A1 (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
UY33925A (es) Inhibidores tricíclicos de quinasas
NI201400125A (es) Antagonistas de st2l y métodos de uso
UY34536A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
UY34765A (es) Compuestos novedosos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
UY34418A (es) Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia
UY34697A (es) Métodos para preparar análogos de nucleótidos
UY34778A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?.
UY4211Q (es) Pizarra para marcadores
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
UY34302A (es) COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA
UY34817A (es) Tienopirimidinas
UY34792A (es) ?método de uso de profungicidas de uk-2a para control de la roya de soja?.
UY34797A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
DOP2013000307A (es) Antagonistas de trpv4
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210526